We are live on ! Find out more
ProShare Advisors

ProShare Advisors Portfolio holdings

AUM $67.5B
1-Year Est. Return 28.09%
This Fund
S&P 500
This Quarter Est. Return
+9.54%
1 Year Est. Return
+28.09%
3 Year Est. Return
+88.43%
5 Year Est. Return
+118.21%
10 Year Est. Return
+464.8%
AUM
$21.6B
AUM Growth
+$3.73B
Cap. Flow
+$2.14B
Cap. Flow %
9.89%
Top 10 Hldgs %
20.71%
Holding
1,837
New
181
Increased
1,318
Reduced
286
Closed
50

Top Buys

Rank Stock Value
1
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$34M
2
XOM icon
ExxonMobil
XOM
+$33.1M
3
JNJ icon
Johnson & Johnson
JNJ
+$32.7M
4
MMM icon
3M
MMM
+$32.4M
5
MCD icon
McDonald's
MCD
+$32.3M

Sector Composition

Rank Sector Weight
1 Technology 20.41%
2 Financials 12.4%
3 Industrials 11.69%
4 Healthcare 11.57%
5 Consumer Staples 11.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PE
1401
DELISTED
PARSLEY ENERGY INC
PE
$274K ﹤0.01%
14,498
-1,067
-7% -$17.6K
ENOV icon
1402
Enovis
ENOV
$1.56B
$273K ﹤0.01%
+4,356
New +$246K
HUBG icon
1403
HUB Group
HUBG
$3.01B
$273K ﹤0.01%
10,628
+1,536
+17% +$38K
WGO icon
1404
Winnebago Industries
WGO
$870M
$273K ﹤0.01%
+5,144
New +$240K
ADAM
1405
Adamas Trust
ADAM
$777M
$272K ﹤0.01%
10,922
+2,592
+31% +$64.3K
MINI
1406
DELISTED
Mobile Mini Inc
MINI
$272K ﹤0.01%
7,162
+935
+15% +$35.2K
SC
1407
DELISTED
SANTANDER CONSUMER USA HOLDINGS INC
SC
$271K ﹤0.01%
11,591
-629
-5% -$15.3K
DNOW icon
1408
DNOW Inc
DNOW
$2.63B
$269K ﹤0.01%
23,942
+3,369
+16% +$37.6K
PACB icon
1409
Pacific Biosciences
PACB
$422M
$269K ﹤0.01%
52,389
-5,231
-9% -$26.6K
HRTX icon
1410
Heron Therapeutics
HRTX
$86.3M
$268K ﹤0.01%
+11,395
New +$252K
EGRX
1411
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$268K ﹤0.01%
4,468
-525
-11% -$31.3K
PRAA icon
1412
PRA Group
PRAA
$648M
$267K ﹤0.01%
7,351
+1,074
+17% +$38K
PRO
1413
DELISTED
PROS Holdings
PRO
$267K ﹤0.01%
4,460
+711
+19% +$41K
RNST icon
1414
Renasant Corp
RNST
$4.01B
$267K ﹤0.01%
7,547
+1,053
+16% +$37.2K
QTTB icon
1415
Q32 Bio
QTTB
$450M
$267K ﹤0.01%
716
-102
-12% -$29.2K
MTOR
1416
DELISTED
MERITOR, Inc.
MTOR
$267K ﹤0.01%
+10,207
New +$230K
CATM
1417
DELISTED
Cardtronics plc Class A Ordinary Shares (UK)
CATM
$267K ﹤0.01%
+5,980
New +$227K
IMGN
1418
DELISTED
Immunogen Inc
IMGN
$266K ﹤0.01%
52,031
-5,065
-9% -$17.2K
FLXN
1419
DELISTED
Flexion Therapeutics, Inc.
FLXN
$266K ﹤0.01%
12,833
-1,330
-9% -$22.4K
GTN icon
1420
Gray Television
GTN
$407M
$265K ﹤0.01%
12,346
+1,972
+19% +$36.6K
KRG icon
1421
Kite Realty
KRG
$5.95B
$265K ﹤0.01%
13,544
+1,978
+17% +$35.7K
ROCK icon
1422
Gibraltar Industries
ROCK
$1.34B
$265K ﹤0.01%
5,263
+770
+17% +$38.7K
AKBA icon
1423
Akebia Therapeutics
AKBA
$327M
$264K ﹤0.01%
41,725
-3,901
-9% -$18.5K
ELAN icon
1424
Elanco Animal Health
ELAN
$12.4B
$263K ﹤0.01%
8,917
+141
+2% +$3.83K
NMRK icon
1425
Newmark Group
NMRK
$2.73B
$262K ﹤0.01%
19,469
+3,109
+19% +$36.3K

Similar funds

ProShare Advisors's Q4 2019 Portfolio in Review

As of Q4 2019, ProShare Advisors held 1,837 positions worth $21.6B, up 21% from $17.9B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

ProShare Advisors deployed $2.14B of net new capital in Q4 2019, opening 181 new positions and adding to 1,318 existing holdings. Its largest new stake was Pennant Group: 484,308 shares worth $16M.

By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was W.R. Berkley, an estimated $12.8M trimmed.

  • ProShare Advisors's largest Q4 2019 buy was Pennant Group: 484,308 shares worth $16M.
  • ProShare Advisors added most to Alphabet (Google) Class A in Q4 2019, an estimated $34M increase.
  • ProShare Advisors's biggest Q4 2019 reduction was W.R. Berkley, cutting an estimated $12.8M.
  • ProShare Advisors fully exited Celgene Corp in Q4 2019, selling an estimated $70M.
  • ProShare Advisors's ten largest holdings make up 21% of its $21.6B portfolio in Q4 2019.
  • ProShare Advisors opened 181 new positions and closed 50 in Q4 2019.
  • ProShare Advisors's portfolio value rose 21% quarter-over-quarter to $21.6B.

Based on ProShare Advisors's 13F filing for Q4 2019, filed 12 Feb 2020.